|
ReoProŽ (abciximab)
ReoPro is a monoclonal antibody with specific properties that noncompetitively blocks the final common pathway to platelet aggregation, the glycoprotein (GP) IIb/IIIa receptor.
ReoPro has shown consistent benefit in 4 pivotal landmark trials (EPIC, CAPTURE, EPILOG, EPISTENT) in reducing ischemic complications in PCI patients. ...
|